Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Comment by mining4dollarson May 09, 2013 5:23pm
124 Views
Post# 21359386

RE: RE: TRADING HALT

RE: RE: TRADING HALT

Why managment feels the need to push forward with a massively dillutive financing, while they currently have enough cash on hand to get them through the summer and 007 clearly at the stage that  many suitors would love to strike a licensing deal with is absolutely beyond me. 

I hope every single person on here calls management to find out exactly where their head is at with this. Only people I see this benefiting is the institutions.

Contacts:

iCo Finance: John Meekison, CFO.  604-602-9414 meekison@icotherapeutics.com

Equicom Group: Michael Moore, Investor Relations 619-467-7067 mmoore@equicomgroup.com

 

 

 

Bullboard Posts